Diagnosis of gastric cancer by measuring the urinary porphyrins after oral administration of 5-aminolevulinic acid (ALA).

Not Applicable

• Conditions: Gastric cancer

• Registration Number: JPRN-UMIN000032048
• Lead Sponsor: Osaka Police Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-04-01
• Study Completion: 2019-03-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with severe anamnesis (Malignant hypertension. With severe congestive heart failure. Severe liver failure. Myocardial infarction within 3 months. End-stage cirrhosis. Poorly controlled diabetes. Severe pulmonary fibrosis. Interstitial pneumonia activity) 2) Patients who are able to orally intake foods. 3) Patients with porphyria or hypersensitivity to porphyrins allergy 4) Cancer patients within 5 years after treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The urinary and serum levels of porphyrins (5-ALA, uroporphyrin I and III, coproporphyrin I and III, protoporphyrin IX) after oral administration of 5-ALA in gastric cancer patients before and after gastrectomy and non-cancer patients.